PBAC's latest decision on Ribavirin: Recommended (2016). Considered for Chronic hepatitis C infection (CHC) in adults, for use in combination therapy with other oral agents. The submission specifically concerned listing of an additional 200 mg tablet strength.
PBAC outcome
Recommended
Restricted
ICER (AUD/QALY)
Not modelled
no economic evaluation
Submissions
6
first 2008
Submissions
6
2008 → 2016
Eligible population
Adult patients with chronic hepatitis C infection requiring combination therapy with other oral agents, including those requiring dose reduction (up to 10% of patients)
Therapy area
Hepatology
Line of therapy
Any
Evidence base
Cost-minimisation
Primary endpoint
Cost-minimisation
Economic model
BIA only
Eligible patients/year
15,000
ICER note
Not modelled — minor submission (additional strength) with no new economic comparison
ICER (historical)
$15k/QALY in an earlier submission (2008) — the latest submission carried no numeric base case. No single PSD states this combined range; see source PSDs.
Submission history
Jul 2008: Recommended — ICER $15k/QALY
Mar 2015: Not recommended · Authority Required
Jul 2015: Recommended with restriction · Restricted
Nov 2015: Recommended · Authority Required
Jul 2016: Recommended with restriction · Restricted